Amendments to the claims:

This listing of claims will replace all prior versions, and listing, of claims in the application:

Claims 1-21 (Cancelled).

22. (New) A method for treatment of Type II diabetes in a human, which comprises administering per day 2 to 8 mg of a thiazolidinedione compound, 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form to a human in need thereof.

23. (New) The method of claim 22 wherein the compound, in pharmaceutically acceptable form, is administered in the form of a pharmaceutical composition from 1 to 2 times per day.

24. (New) The method of claim 22 wherein the pharmaceutically acceptable form of the compound is a pharmaceutically acceptable salt.

25. (New) The method of claim 24 wherein the salt is a maleate salt.

26. (New) The method of claim 22 wherein the pharmaceutically acceptable form of the compound is a pharmaceutically acceptable solvate.

27. (New) The method of claim 26 wherein the solvate is a hydrate.

28. (New) The method of claim 22 wherein the pharmaceutically acceptable form of the compound is a pharmaceutically acceptable solvate of a pharmaceutically acceptable salt.

29. (New) The method of claim 22 wherein the compound, in a pharmaceutically acceptable form, is administered in the form of a tablet or capsule.

30. (New) The method of claim 22, wherein said compound, in pharmaceutically acceptable form, is administered in the form of a tablet.

31. (New) The method of claim 22, wherein the compound is administered in a pharmaceutical composition comprising a pharmaceutically acceptable carrier.

32. (New) The method of claim 31, wherein the pharmaceutically acceptable carrier comprises a disintegrant, a binder, and a diluent.

33. (New) The method of claim 31, wherein the pharmaceutically acceptable carrier comprises sodium starch glycollate.

34. (New) The method of claim 31, wherein the pharmaceutically acceptable carrier comprises methyl cellulose.

35. (New) The method of claim 31, wherein the pharmaceutical acceptable carrier comprises a cellulose or lactose monohydrate.

36. (New) The method of claim 31, wherein the pharmaceutically acceptable carrier comprises one or more of sodium starch glycollate, hydroxpropylmethyl cellulose 2910, microcrystalline cellulose, or lactose monohydrate.

37. (New) The method of claim 31, wherein the pharmaceutically acceptable carrier comprises sodium starch glycollate, hydroxpropylmethyl cellulose 2910, microcrystalline cellulose, and lactose monohydrate.

38. (New) The method of claim 31, wherein the pharmaceutically acceptable carrier comprises a binding agent selected from syrup, acacia, gelatin, sorbitol, tragacanth, and polyvinylpyrollidone.

39. (New) The method of claim 31, wherein the pharmaceutically acceptable carrier comprises a disintegrant selected from starch, polyvinylpyrrolidone, sodium starch glycollate, and microcrystalline cellulose.

40. (New) The method of claim 31, wherein the pharmaceutically acceptable carrier comprises one or more of sodium lauryl sulphate and magnesium stearate.

41. (New) The method of claim 31, wherein the pharmaceutically acceptable carrier comprises one or more of lactose, sugar, maize-starch, calcium phosphate, sorbitol, and glycine.